Congratulations on your new role, tell us a bit about yourself and your
journey to get here?
Thank you. I am originally from Målselv north in Norway and happily married to Erik; together we have two wonderful girls that are 17 years old. When I need to recharge my batteries I like to spend time outside with my family. I have always been interested in sports, and I love spending time in the Norwegian nature.
I graduated from the University of Oslo in 1994, and have more than 20 years of experience in the pharmaceutical industry in Norway and Scandinavia. During these years I have been working in several different positions and departments. I have been Medical Director in Abbott and Business Unit Director of Immunology for AbbVie in both Norway and the last two years in Germany.
Now I am looking forward to taking over as General Manager for AbbVie in Norway, the past years in Germany has provided a lot of experiences that I feel will be an asset in my new role.
What does AbbVie do?
AbbVie is a global, research-driven bio-pharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
What excites you the most about your new role at AbbVie?
I am very excited to take over as head of AbbVie in Norway. This is a strong organization, and I look forward to reaching important goals in the years to come together with all our skilled employees.
AbbVie has been an important driver for developing a strong innovation-based health industry in Norway. I believe this will be even more important in the years ahead of us and I look forward to building on what is already done. I see great opportunities in Norway for an innovation-driven company like AbbVie. And talking about the value chain; it is a large opportunity to increase further the cooperation between the academia, the authorities and pharmaceutical industry to get the new innovative health solutions as fast as possible to the patients.
What challenges do you foresee in the future?
Of course, there are challenges facing us. As we have always done, we will meet these challenges head on with meticulous planning, determination, and execution, and we are confident we will be successful.
AbbVie has a long-term focus, and we will be an important partner in the Norwegian health care environment for many years to come and my goal is that AbbVie should be in the front when it comes to developing sustainable healthcare solutions for the future.
In your opinion, what sets Abbvie apart from other biopharmaceutical
The world needs different approaches to solving increasing global health issues, and AbbVie is dedicated to advancing the standard of care for specific difficult-cure diseases. We are combining the heritage and experience from a big pharma with the future and agility of the biotech industry, to be a leading biopharmaceutical company, I believe this makes us special.